Global Factor IX Deficiency Treatment Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Highlights

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

• Market overview
• Five forces analysis

PART 08: Market segmentation by disease type

• Global hemophilia B drugs market
• Global hemophilia B inhibitors market

PART 09: Market segmentation by type of therapy

• Recombinant therapies
• Plasma-derived therapies

PART 10: Market segmentation by type of disease management

• Prophylaxis
• On-demand therapy
• Inhibitor therapy

PART 11: Geographical segmentation

• Factor IX drugs market in Americas
• Factor IX drugs market in EMEA
• Factor IX drugs market in APAC

PART 12: Market drivers

• Shifting toward half-life drugs
• Special designations promote novel launches
• Growing pipeline with increased focus to meet unmet demand

PART 13: Impact of drivers

PART 14: Market challenges

• Emerging price war in the industry
• Low penetration rate
• Lack of complete remission
• High entry barriers

PART 15: Impact of drivers and challenges

PART 16: Market trends

• Increasing focus on gene therapy
• Increase in investments in the production and discovery
• Strategic initiatives should lead to consolidation

PART 17: Vendor landscape

• Competitive scenario

PART 18: Key vendor analysis

• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire

PART 19: Appendix

• List of abbreviations